首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Curative Effects of ZHENG-Based Fuzheng-Huayu Tablet on Hepatitis B Caused Cirrhosis Related to CYP1A2 Genetic Polymorphism
【24h】

Curative Effects of ZHENG-Based Fuzheng-Huayu Tablet on Hepatitis B Caused Cirrhosis Related to CYP1A2 Genetic Polymorphism

机译:郑氏扶正化瘀片对乙型肝炎肝硬化患者CYP1A2基因多态性的治疗作用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Aim. To investigate the correlation of Fuzheng-Huayu tablet (FZHY) efficacy on chronic hepatitis B caused cirrhosis (HBC) and single nucleotide polymorphisms (SNPs) of CYP1A2. Methods. After 111 cases of HBC with 69 excess, 21 deficiency-excess, and 21 deficiency ZHENGs (ZHENG, also called traditional Chinese medicine syndrome) were treated by FZHY for 6 months, clinical symptoms, Child-Pugh score, and ZHENG score were observed. Three of the SNPs in CYP1A2 gene were detected and analyzed using SNaPshot assay. Results. In ZHENG efficacy between effective and invalid groups, there was significant difference (P < 0.001). The ZHENG deficiency was significantly correlated with FZHY efficacy (P < 0.05). AA genotype of CYP1A2-G2964A was significantly different with GG genotype (P < 0.05) between CYP1A2 Genotypes and FZHY efficacy on ZHENG. More importantly, GA plus AA genotype of CYP1A2-G2964A was significantly different with deficiency ZHENG (P < 0.05) between CYP1A2 genotypes and FZHY efficacy on ZHENG. Conclusion. FZHY improved ZHENG score of HBC, and these efficacies may relate to CYP1A2-G2964A sites. It was suggested that CYP1A2-G2964A locus is probably a risk factor for ZHENG-based FZHY efficacy in HBC.
机译:目标。探讨扶正化瘀片(FZHY)对慢性乙型肝炎肝硬化(HBC)与CYP1A2单核苷酸多态性(SNPs)的相关性。方法。 FZHY治疗111例HBC过量,69例过量,21例不足和21例ZHENG(郑,也称为中医综合症)的HBC患者6个月,观察临床症状,Child-Pugh评分和ZHENG评分。使用SNaPshot分析检测并分析了CYP1A2基因中的三个SNP。结果。有效组和无效组之间的ZHENG疗效之间存在显着差异(P <0.001)。 ZHENG缺乏与FZHY疗效显着相关(P <0.05)。 CYP1A2基因型与FZHY对郑的疗效之间,CYP1A2-G2964A的AA基因型与GG基因型显着不同(P <0.05)。更重要的是,CYP1A2-G2964A的GA加AA基因型与CYP1A2基因型之间的ZHENG缺乏和PZHY对ZHENG的疗效之间存在显着差异(P <0.05)。结论。 FZHY改善了HBC的ZHENG评分,这些功效可能与CYP1A2-G2964A位点有关。有人认为CYP1A2-G2964A基因座可能是HBC中基于ZHENG的FZHY功效的危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号